Menu
1 min read · estimated
APPROVED USE
What FDA approved
Neulasta biosimilar for decreasing infection manifesting as febrile neutropenia in adults and children from birth with nonmyeloid malignancies receiving myelosuppressive anticancer therapy associated with a clinically significant risk of febrile neutropenia.
LAMPGEN ANALYSIS
Why it matters
This long-acting G-CSF biosimilar adds a supportive care option during myelosuppressive treatment.
What research teams should watch
Align administration with the chemotherapy calendar and check the prescribed device and weight-based dose when applicable.
PRIMARY RECORDS